<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Chen X</submitter><funding>Natural Science Foundation of Hunan Province</funding><funding>Basic and Applied Basic Research Foundation of Guangdong Province</funding><funding>National Natural Science Foundation of China</funding><pagination>248</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11539619</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>23(1)</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>SARS-CoV-2, a highly contagious coronavirus, is responsible for the global pandemic of COVID-19 in 2019. Currently, it remains uncertain whether SARS-CoV-2 possesses oncogenic or oncolytic potential in influencing tumor progression. Therefore, it is important to evaluate the clinical and functional role of SARS-CoV-2 on tumor progression.&lt;h4>Methods&lt;/h4>Here, we integrated bioinformatic analysis of COVID-19 RNA-seq data from the GEO database and performed functional studies to explore the regulatory role of SARS-CoV-2 in solid tumor progression, including lung, colon, kidney and liver cancer.&lt;h4>Results&lt;/h4>Our results demonstrate that infection with SARS-CoV-2 is associated with a decreased expression of genes associated with cancer proliferation and metastasis in lung </pubmed_abstract><journal>Molecular cancer</journal><pubmed_title>SARS-CoV-2 nucleocapsid protein interaction with YBX1 displays oncolytic properties through PKM mRNA destabilization.</pubmed_title><pmcid>PMC11539619</pmcid><funding_grant_id>2021A1515011065</funding_grant_id><funding_grant_id>81730061</funding_grant_id><funding_grant_id>32200117</funding_grant_id><funding_grant_id>82072834</funding_grant_id><funding_grant_id>2023JJ60495</funding_grant_id><pubmed_authors>Yang G</pubmed_authors><pubmed_authors>Wu J</pubmed_authors><pubmed_authors>Huang C</pubmed_authors><pubmed_authors>Gu Y</pubmed_authors><pubmed_authors>Luo Z</pubmed_authors><pubmed_authors>Deng M</pubmed_authors><pubmed_authors>Zhang Q</pubmed_authors><pubmed_authors>Liu Y</pubmed_authors><pubmed_authors>Wang N</pubmed_authors><pubmed_authors>Li Y</pubmed_authors><pubmed_authors>Lei Z</pubmed_authors><pubmed_authors>Zhang X</pubmed_authors><pubmed_authors>Pan P</pubmed_authors><pubmed_authors>Jiang B</pubmed_authors><pubmed_authors>Chen X</pubmed_authors><pubmed_authors>Zhou F</pubmed_authors><pubmed_authors>Yue Z</pubmed_authors></additional><is_claimable>false</is_claimable><name>SARS-CoV-2 nucleocapsid protein interaction with YBX1 displays oncolytic properties through PKM mRNA destabilization.</name><description>&lt;h4>Background&lt;/h4>SARS-CoV-2, a highly contagious coronavirus, is responsible for the global pandemic of COVID-19 in 2019. Currently, it remains uncertain whether SARS-CoV-2 possesses oncogenic or oncolytic potential in influencing tumor progression. Therefore, it is important to evaluate the clinical and functional role of SARS-CoV-2 on tumor progression.&lt;h4>Methods&lt;/h4>Here, we integrated bioinformatic analysis of COVID-19 RNA-seq data from the GEO database and performed functional studies to explore the regulatory role of SARS-CoV-2 in solid tumor progression, including lung, colon, kidney and liver cancer.&lt;h4>Results&lt;/h4>Our results demonstrate that infection with SARS-CoV-2 is associated with a decreased expression of genes associated with cancer proliferation and metastasis in lung </description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 Nov</publication><modification>2026-07-15T08:08:15.808Z</modification><creation>2025-04-04T12:01:08.374Z</creation></dates><accession>S-EPMC11539619</accession><cross_references><pubmed>39506849</pubmed><doi>10.1186/s12943-024-02153-1</doi></cross_references></HashMap>